•
Dec 31, 2021
Immunovant Q3 2022 Earnings Report
Reported financial results with cash of approximately $527.0 million.
Key Takeaways
Immunovant reported its financial results for the fiscal quarter ended December 31, 2021. The company ended the quarter with approximately $527.0 million in cash. Net loss was $41.4 million, or $0.36 per common share.
Ended the quarter with approximately $527.0 million in cash.
Research and development expenses were $29.8 million.
General and administrative expenses were $11.5 million.
Net loss was $41.4 million ($0.36 per common share).
Immunovant
Immunovant
Forward Guidance
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws.